Recombinant Human IL-29/IFN-lambda 1 Protein, CF

E. coli-expressed
Catalog # Availability Size / Price Qty
11240-IL-050
Recombinant Human IL-29/IFN-lambda 1 Protein Bioactivity.
1 Image
Product Details
FAQs
Reviews

Recombinant Human IL-29/IFN-lambda 1 Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 0.500-6.00 ng/mL.
Source
E. coli-derived human IL-29/IFN-lambda 1 protein
Pro23-Thr200
Accession #
N-terminal Sequence
Analysis
Pro23
Predicted Molecular Mass
20 kDa
SDS-PAGE
18-22 kDa, under reducing conditions.

Product Datasheets

You must select a language.

x

11240-IL

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11240-IL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity View Larger

Recombinant Human IL‑29/IFN‑lambda 1 Protein (Catalog # 11240-IL) demonstrates anti-viral activity in HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 0.500-6.00 ng/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-29/IFN-lambda 1

IL-29, also known interferon-lambda 1 (IFN lambda 1), along with IL-28A (IFN lambda 2), IL-28B (IFN lambda 3) and IFN lambda 4, collectively comprise the type III subset of IFNs. IFN lambda s are class II cytokine receptor ligands distantly related to both members of the IL-10 family and to the type I IFN family (11-19% amino acid (aa) sequence identity). IL-29 is expressed only in humans and shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively. IFN lambda signaling was initially thought to be restricted to epithelial cells, but, recently, additional cell types have been shown to also respond. IFN lambda s have been shown to be induced by a variety of stimuli from influenza A and herpes viruses to lipopolysaccharides and double-stranded RNA. IL-29 signals through a unique receptor complex composed of IFN lambda R1 (IL-28RA) and the shared IL-10R2 chain, which is also a part of the receptor complexes for IL-10, IL-22, and IL-26. In humans, IL-29 is the most potent IFN lambda molecule, the most abundant IFN lambda molecule in serum, and the only IFN lambda molecule to display N-linked glycosylation. IL-29 is being investigated for its role in immunity, both innate and adaptive, as well as in autoimmune disorders. Additionally, the therapeutic potential of IL-29 in inflammatory diseases and its cancer fighting properties are being actively studied.

References
  1. Vilcek, J. (2003) Nature Immunol. 4:8.
  2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
  3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
  4. Gad, H.H. et al. (2009) J. Biol. Chem. (2009) 284:20869.
  5. Miknis, Z.J. et al. (2010) J. Mol. Biol. 404:650.
  6. Donnelly, R.P. et al. (2010) J. Interferon. Cytokine Res. 30:555.
  7. Lazear, H.M. et al. (2015) Immunity. 43:15.
  8. Ye, L. et al. (2019) Nat. Rev. Immunol. 19:614.
  9. Goel, R.R. et al. (2021) Nat. Rev. Rheumatol. 17:349.
  10. Kelm, N.E. et al. (2016) Crit. Rev. Oncol. Hematol. 106:91.
  11. Wang, J.M. et al. (2019) J. Cell Mol. Med. 23:7926.
Long Name
Interleukin 29
Entrez Gene IDs
282618 (Human)
Alternate Names
cytokine Zcyto21; IFNL1; IFN-lambda 1; IFN-lambda-1; IL29; IL-29; interferon lambda-1; interferon, lambda 1; interleukin 29 (interferon, lambda 1); interleukin-29; ZCYTO21

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human IL-29/IFN-lambda 1 Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human IL-29/IFN-lambda 1 Protein, CF and earn rewards!

Have you used Recombinant Human IL-29/IFN-lambda 1 Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review